

Prognostic Value of Long Noncoding RNA NORAD in Various cancers: a meta-analysis

Qin Yang ^{a, b, 1}, Zheng Zhang ^{c, 1}, Yuan-Yuan Gong ^{a, b, 1}, Zhi-Ran Li ^{a, b}, Hua-Zhu

Zhang ^{a, b}, Gong-Hao He ^{a, b, *}

^a Research Center of Clinical Pharmacology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650032, China.

^b Department of Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Dague Rd., Kunming 650032, China.


^c Medical Engineering Section, The 306th Hospital of PLA, Beijing 100101, China.

Running title: lncRNA NORAD with prognosis of cancer patients

¹ These authors contributed equally to this work.

* Correspondence to: Gong-Hao He, Ph.D., 212 Dague Rd, Kunming 650032, China.

Tel: +86-871-64774793, E-mail: gonghow@hotmail.com.



Supplementary Figure S1. Forest plots for the association between NORAD

expression with clinicopathological parameters in cancer patients. (a) age; (b) gender; (c) differentiation; (d) tumor size; (e) distant metastasis; (f) tumor number; (g) liver cirrhosis; (h) vascular invasion.